Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Status:
RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy